Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cardiac sympathetic overactivity is a well-established contributor to the progression of neurogenic hypertension and heart failure, yet the underlying pathophysiology remains unclear. Recent studies have highlighted the importance of acutely regulated cyclic nucleotides and their effectors in the control of intracellular calcium and exocytosis. Emerging evidence now suggests that a significant component of sympathetic overactivity and enhanced transmission may arise from impaired cyclic nucleotide signalling, resulting from compromised phosphodiesterase activity, as well as alterations in receptor-coupled G-protein activation. In this review, we address some of the key cellular and molecular pathways that contribute to sympathetic overactivity in hypertension and discuss their potential for therapeutic targeting.

Original publication

DOI

10.1113/JP276962

Type

Journal article

Journal

J Physiol

Publication Date

07/2020

Volume

598

Pages

2957 - 2976

Keywords

Autonomic Nervous System, Cardiovascular Disease, Cyclic Nucleotide, Hypertension, Intracellular Calcium, Protein Kinase, Sympathetic Ganglion, Sympathetic Nervous System, Heart, Heart Failure, Humans, Hypertension, Sympathetic Nervous System